


DIRECTORS' REPORT AND ACCOUNTS

YEAR ENDED 31 MARCH 2010

ALIPHARMA LIMITED

COMP. REG. NO. 6091428

THURSDAY



A31

AK1F3QY1

20/01/2011

207

COMPANIES HOUSE

ASHRAF AHMED & CO. CHARTERED ACCOUNTANTS

112 DICKENSON ROAD, MANCHESTER, M14 5HS

ALIPHARMA LIMITED

YEAR ENDED 31 MARCH 2010

CONTENTS

CONTENTS	PAGE
GENERAL	3
DIRECTORS' REPORT	4
STATEMENT OF DIRECTORS' RESPONSIBILITIES	5
ACCOUNTANTS' REPORT	6
BALANCE SHEET	7
PROFIT AND LOSS ACCOUNTS	8 TO 9
NOTES FORMING PARTS OF THE ACCOUNTS	10 TO 12

ALIPHARMA LIMITED

YEAR ENDED 31 MARCH 2010

GENERAL

BUSINESS ADDRESSES

287B Stretford Road
Urmston
Manchester
M41 9NU

11 Thornley Street
Hyde
Cheshire
SK14 1JY

DIRECTORS

Muhammad Abdulmalik Ali

SECRETARY AND REGISTERED OFFICE

Mrs Shanaz Ali

287B Stretford Road
Urmston
Manchester
M41 9NU

ACCOUNTANTS/AUDITORS

Ashraf Ahmed & Co
Chartered Accountants
112 Dickenson Road
Rusholme
Manchester
M14 5HS

BANKERS

HSBC

ALIPHARMA LIMITED

REPORT OF THE DIRECTORS

FOR THE YEAR ENDED 31 MARCH 2010

The Directors present their annual report and the accounts for the year ended 31 March 2010

PRINCIPAL ACTIVITIES

The principal activities of the company throughout the year were pharmaceutical


DIRECTORS

The directors who served during the year were as follows:-

Mohammad Abdulmalik Ali

The above report have been prepared in accordance with small company regime of the Companies Act 2006

By order of the board



Mrs Shanaz Ali
Secretary

ALIPHARMA LIMITED

STATEMENT OF DIRECTORS' RESPONSIBILITIES

FOR THE YEAR ENDED 31 MARCH 2010

The Directors, as required by the Company Law, prepared the annual report and the accounts in accordance with United Kingdom Accounting Standards and applicable law for the year ended 31 March 2010, which give a true and fair view of the state of affairs of the company for that period. In preparing These accounts, the Directors have -

- i) selected suitable accounting policies and applied these consistently,
- ii) made judgement and estimates that are reasonable and prudent,
- iii) prepared the financial statement on the going concern basis,

The Directors have been keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and enable the directors to ensure that the accounts comply with the Companies Act 2006. In addition, the directors have taken reasonable steps in safeguarding the assets of the company, preventing and detecting of fraud and other irregularities.

ALIPHARMA LIMITED

CHARTERED ACCOUNTANT'S REPORT TO THE BOARD OF DIRECTORS

ON THE UNAUDITED FINANCIAL STATEMENT

FOR THE YEAR ENDED 31 MARCH 2010


In accordance with the engagement letter dated 4 September 2008, and in order to assist you to fulfil your duties under the Companies Act 2006, we have compiled the financial statements of the company which comprises the Profit and Loss Account, The Balance Sheet and the related notes from the accounting records and information and explanations that you have given to us

This report is made to Company's Board of Directors, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the Company's Board of Directors that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's Board of Directors, as a body, for our work or for this report

We have carried out this engagement in accordance with technical guidance issued by the Institute of Chartered Accountants in England and Wales and have complied with the ethical guidance laid down by the Institute relating to members undertaking the compilation of financial statements

You have acknowledged on the balance sheet as at 31 March 2010 your duty to ensure that the company has kept proper accounting records and to prepare financial statements that give a true and fair view under the Companies Act 2006. You consider that the company is exempt from the statutory requirement for an audit for the year

We have not been instructed to carry out an audit of the financial statements. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion in the financial statements



Ashraf Ahmed & Co
Chartered Accountants

112 Dickenson Road
Manchester
M14 5HS

ALIPHARMA LIMITED

BALANCE SHEET AS AT 31 MARCH 2010

	<u>NOTES</u>	<u>£</u>	<u>£</u>
FIXED ASSETS			
Tangible assets	5		157,488
CURRENT ASSETS			
Stock	1	144,266	
Debtors and prepayments		514,268	
Cash at bank and in hand		<u>79,512</u>	
		738,046	
CREDITORS			
Amounts due within one year	6	<u>-693,405</u>	
Net current assets/liabilities		44,641	<u>44,641</u>
			202,129
CREDITORS			
Amount due after more than one year	7		<u>-25,000</u>
Net assets			<u>177,129</u>
FINANCED BY:			
CAPITAL AND RESERVES			
Called up share capital	8		100
Retained profit/ Loss			<u>177,029</u>
			<u>177,129</u>

STATEMENT OF THE DIRECTORS

For the year ended 31 March 2010 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006

The members have not required the company to obtain an audit in accordance with Section 476 of the Companies Act 2006.

The Directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of the accounts

These accounts were approved by the board of directors on 17 January 2011 and were signed on its behalf by -



Muhammad Abdulmalik Ali
Director

ALIPHARMA LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2010

	NOTES	£
Gross profit		520,996
Staff costs	10	-218,978
Depreciation on tangible fixed assets		-9,391
Other operating charges		<u>-65,123</u>
Operating profit/ loss		227,504
Other interest receivable		-
Interest payable and similar charges		<u>-1,537</u>
Profit on ordinary activities before taxation		225,967
Tax on profit on ordinary activities		<u>-45,700</u>
Profit/ loss for the financial year		180,267
Dividend proposed		<u>-100,000</u>
Retained profit/loss for the financial year		<u>80,267</u>

There were no recognised gains or losses other than those shown above

The above notes form an integral part of these accounts

ALIPHARMA LIMITED

TRADING, PROFIT AND LOSS ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2010

	NOTES	£
SALES	1	1,824,358
COST OF SALES	9	<u>-1,304,457</u>
GROSS PROFIT		519,901
COMMISSION		<u>1,095</u>
		<u>520,996</u>
DISTRIBUTION AND ADMINISTRATIVE EXPENSES		
Directors' remuneration		11,566
Wages and NIC		78,895
Professional cahrges (locum fees)		128,517
Rent, rates and services charge		21,987
Insurance		644
Heat and light		5,055
Telephone		2,212
Printing, stationery and advertising		3,583
Repairs and renewals		2,219
Motor and travelling expenses		5,949
Laundry and cleaning		739
Software maintenance and technical support		5,254
Book keeping charges		2,220
Legal charges		1,217
Bank charges		1,537
Accountancy charges		4,862
Subscription and journals		8,660
Sundry expenses		522
Depreciation		<u>9,391</u>
		295,029
Trading profit for the year		<u>225,967</u>
		<u>520,996</u>

There were no recognised gains or losses other than those shown above

The accompanying notes form an integral part of these accounts

ALIPHARMA LIMITED

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2010

1 ACCOUNTING POLICIES

The following accounting policies have been consistently applied in dealing with the items which are considered material in relation to the company's accounts

Basis of preparation

The accounts have been prepared under the historical cost accounting rules (and in accordance with the Financial Reporting Standard for Smaller Entities).

Turnover

Turnover represents the amounts (excluding Value Added Tax) derived from provision of goods and services to customers during the year

Fixed assets and depreciation

Depreciation is provided by the company to write off the cost of valuation less the estimated residual value of its tangible fixed assets by equal annual instalments over their useful economic lives as follows:-

Plant, machinery and equipment	15%
--------------------------------	-----

Stocks

Stocks are valued by professional stock takers as at 31 March 2010

2 TURNOVER

Turnover is attributable to the principal activity of the company i.e pharmaceutical

3 OPERATING PROFIT/LOSS

After charging -

	£
Directors' emoluments	11,566
Depreciation of tangible assets	9,391

ALIPHARMA LIMITED

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2010

4 DIVIDENDS

Dividends were declared during the year but not paid

5 TANGIBLE FIXED ASSETS

	<u>Goodwill</u>	<u>Lease- hold</u>	<u>Fixtures & Equipment</u>	<u>Motor Vehicle</u>	<u>Total</u>
	£	£	£		£
Cost at the beginning of the year	100,000	9,272	37,066	14,000	160,338
Addition	-	<u>1,702</u>	<u>4,291</u>	<u>9,608</u>	<u>15,601</u>
Cost at the end of the year	<u>100,000</u>	<u>10,974</u>	<u>41,357</u>	<u>23,608</u>	<u>175,939</u>

DEPRECIATION

At the beginning of the year	-	-	5,560	3,500	9,060
Charge for the year	-	-	<u>5,370</u>	<u>4,021</u>	<u>9,391</u>
	-	-	<u>10,930</u>	<u>7,521</u>	<u>18,451</u>
Net book value	<u>100,000</u>	<u>10,974</u>	<u>30,427</u>	<u>16,087</u>	<u>157,488</u>

6 CREDITORS

Amounts falling due within one year -	£
Bank overdraft	-
Trade creditors and accruals	347,138
Inland Revenue	58,185
Customs & Excise	-
Directors' loan account	<u>288,082</u>
	<u>693,405</u>

7 CREDITORS

Amounts falling due after more than a year	£25,000
--	---------

ALIPHARMA LIMITED

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2010

8 CALLED UP SHARE CAPITAL

£

Authorised - ordinary shares of £1 each	<u>100</u>
Allotted, called up and fully paid ordinary share of £1 each	<u>100</u>

9 COST OF SALES

Opening stock	48,106
Purchases	<u>1,400,617</u>
	1,448,723
Less closing stock	<u>-144,266</u>
	<u>1,304,457</u>

10 STAFFS' COSTS

Wages plus locum fees

11 POST BALANCE SHEET EVENTS

There have been no events since the balance sheet date, which affect the position of the company